Multimodal genomic features predict outcome of immune checkpoint blockade in non-small-cell lung cancer
V Anagnostou, N Niknafs, K Marrone, DC Bruhm…�- Nature cancer, 2020 - nature.com
Despite progress in immunotherapy, identifying patients that respond has remained a
challenge. Through analysis of whole-exome and targeted sequence data from 5,449�…
challenge. Through analysis of whole-exome and targeted sequence data from 5,449�…
Harmonization of tumor mutational burden quantification and association with response to immune checkpoint blockade in non–small-cell lung cancer
PURPOSE Heterogeneity in tumor mutational burden (TMB) quantification across
sequencing platforms limits the application and further study of this potential biomarker of�…
sequencing platforms limits the application and further study of this potential biomarker of�…
[HTML][HTML] A gene mutation signature predicting immunotherapy benefits in patients with NSCLC
Introduction Identification of patients who can benefit from immune checkpoint blockade
(ICB) therapy is key for improved clinical outcome. Recently, US Food and Drug�…
(ICB) therapy is key for improved clinical outcome. Recently, US Food and Drug�…
Comprehensive genomic profiling identifies novel genetic predictors of response to anti–PD-(L) 1 therapies in non–small cell lung cancer
Purpose: Immune checkpoint inhibitors (ICI) have revolutionized cancer management.
However, molecular determinants of response to ICIs remain incompletely understood�…
However, molecular determinants of response to ICIs remain incompletely understood�…
Tumor mutational burden assessed by targeted NGS predicts clinical benefit from immune checkpoint inhibitors in non‐small cell lung cancer
I Alborelli, K Leonards, SI Rothschild…�- The Journal of�…, 2020 - Wiley Online Library
In non‐small cell lung cancer (NSCLC), immune checkpoint inhibitors (ICIs) significantly
improve overall survival (OS). Tumor mutational burden (TMB) has emerged as a predictive�…
improve overall survival (OS). Tumor mutational burden (TMB) has emerged as a predictive�…
[HTML][HTML] Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer
Abstract Anti-PD-1/PD-L1 agents have transformed the treatment landscape of advanced
non-small cell lung cancer (NSCLC). To expand our understanding of the molecular features�…
non-small cell lung cancer (NSCLC). To expand our understanding of the molecular features�…
[HTML][HTML] Genomic features of response to combination immunotherapy in patients with advanced non-small-cell lung cancer
Combination immune checkpoint blockade has demonstrated promising benefit in lung
cancer, but predictors of response to combination therapy are unknown. Using whole-exome�…
cancer, but predictors of response to combination therapy are unknown. Using whole-exome�…
Integration of comprehensive genomic profiling, tumor mutational burden, and PD‐L1 expression to identify novel biomarkers of immunotherapy in non‐small cell lung�…
Y Shi, Y Lei, L Liu, S Zhang, W Wang, J Zhao…�- Cancer�…, 2021 - Wiley Online Library
Objectives This study aimed to explore the novel biomarkers for immune checkpoint inhibitor
(ICI) responses in non‐small cell lung cancer (NSCLC) by integrating genomic profiling�…
(ICI) responses in non‐small cell lung cancer (NSCLC) by integrating genomic profiling�…
[HTML][HTML] Co-occurring genomic alterations and immunotherapy efficacy in NSCLC
F Zhang, J Wang, Y Xu, S Cai, T Li, G Wang…�- NPJ Precision�…, 2022 - nature.com
An oncogene-centric molecular classification paradigm in non-small cell lung cancer
(NSCLC) has been established. Of note, the heterogeneity within each oncogenic driver�…
(NSCLC) has been established. Of note, the heterogeneity within each oncogenic driver�…
[HTML][HTML] Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer
MV Negrao, F Skoulidis, M Montesion…�- …�for immunotherapy of�…, 2021 - ncbi.nlm.nih.gov
Background Non-small cell lung cancer (NSCLC) patients bearing targetable oncogene
alterations typically derive limited benefit from immune checkpoint blockade (ICB), which�…
alterations typically derive limited benefit from immune checkpoint blockade (ICB), which�…